Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

NCT02102594 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped recruitment difficulties

Conditions

Myasthenia Gravis
Systemic Lupus Erythematosus
Rheumatoid Arthritis

Interventions

DRUG: Bortezomib

Sponsor

Charite University, Berlin, Germany

Collaborators

[object Object]
[object Object]